PL1698640T5 - Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu - Google Patents

Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu

Info

Publication number
PL1698640T5
PL1698640T5 PL04773700T PL04773700T PL1698640T5 PL 1698640 T5 PL1698640 T5 PL 1698640T5 PL 04773700 T PL04773700 T PL 04773700T PL 04773700 T PL04773700 T PL 04773700T PL 1698640 T5 PL1698640 T5 PL 1698640T5
Authority
PL
Poland
Prior art keywords
antibody
stabilizing
stabilized solution
type
preparation
Prior art date
Application number
PL04773700T
Other languages
English (en)
Other versions
PL1698640T3 (pl
Inventor
Yuji Ueno
Takashi Kayashita
Atsushi Ishihara
Masashi Nakakura
Kyoko Yamauchi
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34419308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1698640(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of PL1698640T3 publication Critical patent/PL1698640T3/pl
Publication of PL1698640T5 publication Critical patent/PL1698640T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL04773700T 2003-10-01 2004-10-01 Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu PL1698640T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003343645 2003-10-01
EP04773700.2A EP1698640B2 (en) 2003-10-01 2004-10-01 Method of stabilizing antibody and stabilized solution-type antibody preparation
PCT/JP2004/014903 WO2005033143A1 (ja) 2003-10-01 2004-10-01 抗体の安定化方法及び安定化された溶液状抗体製剤

Publications (2)

Publication Number Publication Date
PL1698640T3 PL1698640T3 (pl) 2016-05-31
PL1698640T5 true PL1698640T5 (pl) 2019-12-31

Family

ID=34419308

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04773700T PL1698640T5 (pl) 2003-10-01 2004-10-01 Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu

Country Status (15)

Country Link
US (3) US8496930B2 (pl)
EP (2) EP1698640B2 (pl)
JP (1) JP4219932B2 (pl)
KR (1) KR100911091B1 (pl)
CN (1) CN100522998C (pl)
AU (1) AU2004277466C1 (pl)
CA (1) CA2540848C (pl)
CY (1) CY1117215T1 (pl)
DK (1) DK1698640T4 (pl)
ES (1) ES2562912T5 (pl)
HU (1) HUE026793T2 (pl)
PL (1) PL1698640T5 (pl)
PT (1) PT1698640E (pl)
SI (1) SI1698640T2 (pl)
WO (1) WO2005033143A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
SI1698640T2 (sl) * 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2007016562A2 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
US8945564B2 (en) * 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
AU2008205512B2 (en) * 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ622583A (en) * 2007-11-30 2015-08-28 Abbvie Biotechnology Ltd Protein formulations and methods of making same
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
RU2560701C2 (ru) * 2009-05-04 2015-08-20 Эббви Байотекнолоджи Лтд. Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа
CN102802668A (zh) 2009-06-04 2012-11-28 Alk股份公司 包含至少一种肾上腺素能化合物的稳定化组合物
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
US8795658B2 (en) 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
JP6527697B2 (ja) 2013-01-28 2019-06-05 国立大学法人 熊本大学 タンパク質を安定化させたゲル状製剤
EP3021833B2 (en) * 2013-07-19 2022-03-30 Hexal Aktiengesellschaft Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
CN103772505B (zh) * 2013-12-18 2014-10-15 长春博迅生物技术有限责任公司 一种抗体试剂保存液
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
EP3930757A1 (en) 2019-03-01 2022-01-05 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
AU2020364436A1 (en) * 2019-10-11 2022-04-21 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody
CN117642180A (zh) * 2021-05-05 2024-03-01 I2O治疗公司 用于治疗炎性疾病和自身免疫性疾病的离子液体制剂
WO2023086499A1 (en) 2021-11-10 2023-05-19 I2O Therapeutics, Inc. Ionic liquid compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US421777A (en) * 1890-02-18 Straining-pot
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS62194459A (ja) 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DK0639202T3 (da) 1992-04-30 1999-08-09 Cor Therapeutics Inc Stabil polypeptidsammensætning
JPH06189781A (ja) * 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
ES2225874T3 (es) * 1995-03-10 2005-03-16 Genentech, Inc. Activacion de receptor mediante gas.
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
CA2371427A1 (en) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
ES2301491T3 (es) 1999-09-30 2008-07-01 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo humano de trasplante con region de determinacion de la complementariedad contra gangliosido gd3 y derivados del anticuerpo contra gangliosido gd3.
WO2001047554A1 (fr) * 1999-12-28 2001-07-05 Chugai Seiyaku Kabushiki Kaisha Compositions d'anticorps stables et preparations pour injection
CA2401491C (en) 2000-03-03 2011-07-05 Kyowa Kirin Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
US8632778B2 (en) * 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
JP2005522996A (ja) 2001-11-02 2005-08-04 セントカー・インコーポレーテツド Ｒｓｖタンパク質、抗体、組成物、方法および使用
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
SI1698640T2 (sl) * 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina

Also Published As

Publication number Publication date
DK1698640T3 (en) 2016-02-15
EP1698640B1 (en) 2015-12-30
PT1698640E (pt) 2016-03-31
US20070020255A1 (en) 2007-01-25
KR100911091B1 (ko) 2009-08-06
DK1698640T4 (da) 2019-09-02
EP1698640A1 (en) 2006-09-06
KR20060089227A (ko) 2006-08-08
JPWO2005033143A1 (ja) 2007-11-15
CY1117215T1 (el) 2017-04-05
HK1090933A1 (en) 2007-01-05
SI1698640T1 (sl) 2016-03-31
US20130280248A1 (en) 2013-10-24
ES2562912T5 (es) 2020-02-18
HUE026793T2 (en) 2016-07-28
US9011850B2 (en) 2015-04-21
WO2005033143A1 (ja) 2005-04-14
EP3006463A1 (en) 2016-04-13
SI1698640T2 (sl) 2019-08-30
CN1856507A (zh) 2006-11-01
PL1698640T3 (pl) 2016-05-31
CA2540848A1 (en) 2005-04-14
EP1698640B2 (en) 2019-06-19
AU2004277466C1 (en) 2022-06-23
US8496930B2 (en) 2013-07-30
JP4219932B2 (ja) 2009-02-04
AU2004277466B2 (en) 2010-04-01
EP1698640A4 (en) 2008-09-17
US20150190507A1 (en) 2015-07-09
US10172790B2 (en) 2019-01-08
ES2562912T3 (es) 2016-03-09
CN100522998C (zh) 2009-08-05
AU2004277466A1 (en) 2005-04-14
CA2540848C (en) 2012-12-11

Similar Documents

Publication Publication Date Title
PL1698640T5 (pl) Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
TWI367766B (en) Immunoglobulin formulation and method of preparation thereof
HUE038498T2 (hu) Immunglobulin készítmény és elõállítási módszere
EP1482984A4 (en) REPLACEMENT ANTIBODIES AND METHOD FOR THEIR MANUFACTURE AND USE
ZA200305825B (en) Modified antibodies and methods of use
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1648316A4 (en) VERTEBRAL RETENTION AND CLEARANCE DEVICE AND METHOD OF USE
IL169648A0 (en) Novel structures and method of preparation
AU2003277259A8 (en) Immunoassay and method of use
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
GB0511621D0 (en) Peltier based freeze-thaw valves and method of use
EP1578917A4 (en) MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
PL1667624T3 (pl) Układ zamknięcia i sposób wytwarzania
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
IL172533A0 (en) Humanized anti-ccr2 antibodies and methods of use
GB0304555D0 (en) Compounds and methods of manufacture
EP1680489A4 (en) EMULSION FUEL AND PROCESS FOR PREPARING THE SAME
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
EP1616020A4 (en) ANTI-CR1 ANTIBODIES WITH REDUCED IMMUNOGENICITY AND COMPOSITIONS AND TREATMENT METHODS BASED ON THEM
PL356624A1 (pl) Wódka gatunkowa oraz sposób jej sporządzania
EP1592343A4 (en) METHOD AND SYSTEM FOR DETERMINING BLOOD CHARACTERISTICS
PL356684A1 (pl) Sposób otrzymywania preparatów dietetyczno-leczniczych oraz ich zastosowanie